ダウンロード数: 79
このアイテムのファイル:
ファイル | 記述 | サイズ | フォーマット | |
---|---|---|---|---|
68_11_337.pdf | 1.77 MB | Adobe PDF | 見る/開く |
タイトル: | 長期制癌にてアンドロゲン遮断療法を中止した限局性前立腺癌症例の検討 |
その他のタイトル: | Evaluation of Patients with Localized Prostate Cancer in whom Long-Term Successful Androgen Deprivation Therapy was Ceased |
著者: | 荒木, 博賢 伊藤, 克弘 五十嵐, 篤 三浦, 高慶 宮﨑, 有 三品, 睦輝 奥野, 博 |
著者名の別形: | ARAKI, Hiromasa ITO, Katsuhiro IGARASHI, Atsushi MIURA, Takayoshi MIYAZAKI, Yu MISHINA, Mutsuki OKUNO, Hiroshi |
キーワード: | Prostate cancer Androgen deprivation therapy Cessation |
発行日: | 30-Nov-2022 |
出版者: | 泌尿器科紀要刊行会 |
誌名: | 泌尿器科紀要 |
巻: | 68 |
号: | 11 |
開始ページ: | 337 |
終了ページ: | 343 |
抄録: | We evaluated the clinical course of patients with localized prostate cancer in whom long-term successful androgen deprivation therapy (ADT) was ceased. Study subjects were 24 patients with stage B prostate cancer who were initially treated with ADT for a median duration of 93 months. The median age at the cessation of ADT was 84 years. The median nadir serum prostate specific antigen (PSA) level was 0.022 ng/ml. The median duration of follow-up from the cessation of ADT was 31 months. During follow-up, five patients showed PSA elevation of ≥2 ng/ml from the nadir. Serum testosterone level was tested in 20 patients, and five showed testosterone recovery ≥0.5 ng/ml. Seven patients died from diseases other than prostate cancer, but there were no deaths caused by prostate cancer. This study demonstrated that long-term successful ADT for localized prostate cancer could be ceased with adequate follow-up evaluation. |
著作権等: | 許諾条件により本文は2023-12-01に公開 |
DOI: | 10.14989/ActaUrolJap_68_11_337 |
URI: | http://hdl.handle.net/2433/277638 |
PubMed ID: | 36458396 |
出現コレクション: | Vol.68 No.11 |
このリポジトリに保管されているアイテムはすべて著作権により保護されています。